Complex Arrhythmia Registry

A regiszterben nem jelölt feltételek

• Atrial Fibrillation (AF) Cohort:
  • Inclusion Criteria (Patients must meet ALL of the following criteria):
  • Age ≥ 18 years.
  • Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF).
  • Scheduled to undergo first-time catheter ablation for AF.
  • Procedure to be performed using a 3D mapping system.
  • Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.
  • Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):
  • Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries).
  • AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication).
  • Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment/procedure.
  • Severe active infection (e.g., septic shock, sepsis).
  • Contraindications to anticoagulation therapy.
  • Current participation in another interventional clinical trial that may confound the results of this study.
  • Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.
• Ventricular Tachycardia (VT) Cohort
  • Inclusion Criteria (Patients must meet ALL of the following criteria):
  • Age ≥ 18 years.
  • Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including:
  • Ischemic heart disease (e.g., prior MI, coronary artery disease).
  • Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)).
  • Scheduled to undergo first-time catheter ablation for VT.
  • Procedure to be performed using a 3D mapping system.
  • Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.
  • Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):
  • VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance).
  • Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease).
  • Cardiac surgery within 60 days prior to the planned ablation procedure.
  • Severe coagulopathy (e.g., platelet count < 50 x 10⁹/L, disseminated intravascular coagulation (DIC)).
  • Severe heart failure with left ventricular ejection fraction (LVEF) < 20%.
  • Severe active infection (e.g., septic shock, sepsis).
  • Current participation in another interventional clinical trial that may confound the results of this study.
  • Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.